Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Anupama Munshi and Rajagopal Ramesh.
Anupama Munshi
Connection Strength
7.231
Rajagopal Ramesh
  1. Interleukin (IL)-24: Reconfiguring the Tumor Microenvironment for Eliciting Antitumor Response. Adv Exp Med Biol. 2021; 1290:99-110.
    View in: PubMed
    Score: 0.755
  2. Mitogen-activated protein kinases and their role in radiation response. Genes Cancer. 2013 Sep; 4(9-10):401-8.
    View in: PubMed
    Score: 0.454
  3. Exosomes in diagnostic and therapeutic applications of ovarian cancer. J Ovarian Res. 2024 May 25; 17(1):113.
    View in: PubMed
    Score: 0.239
  4. Tumor-targeted exosomes for delivery of anticancer drugs. Cancer Lett. 2023 04 01; 558:216093.
    View in: PubMed
    Score: 0.219
  5. RNA binding proteins (RBPs) and their role in DNA damage and radiation response in cancer. Adv Drug Deliv Rev. 2022 Dec; 191:114569.
    View in: PubMed
    Score: 0.213
  6. Organically derived exosomes as carriers of anticancer drugs and imaging agents for cancer treatment. Semin Cancer Biol. 2022 Feb 19.
    View in: PubMed
    Score: 0.204
  7. Drug delivery approaches for HuR-targeted therapy for lung cancer. Adv Drug Deliv Rev. 2022 01; 180:114068.
    View in: PubMed
    Score: 0.201
  8. Therapeutic approaches targeting molecular signaling pathways common to diabetes, lung diseases and cancer. Adv Drug Deliv Rev. 2021 11; 178:113918.
    View in: PubMed
    Score: 0.197
  9. Extracellular Vesicles in Oncology: from Immune Suppression to Immunotherapy. AAPS J. 2021 02 14; 23(2):30.
    View in: PubMed
    Score: 0.190
  10. Molecular Targeting of HuR Oncoprotein Suppresses MITF and Induces Apoptosis in Melanoma Cells. Cancers (Basel). 2021 Jan 06; 13(2).
    View in: PubMed
    Score: 0.189
  11. Exosomes as drug delivery vehicle and contributor of resistance to anticancer drugs. Cancer Lett. 2020 08 28; 486:18-28.
    View in: PubMed
    Score: 0.181
  12. Progress in extracellular vesicle biology and their application in cancer medicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 07; 12(4):e1621.
    View in: PubMed
    Score: 0.178
  13. Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage. Int J Radiat Biol. 2021; 97(8):1109-1120.
    View in: PubMed
    Score: 0.178
  14. Tumor-Targeted Dendrimer Nanoparticles for Combinatorial Delivery of siRNA and Chemotherapy for Cancer Treatment. Methods Mol Biol. 2020; 2059:167-189.
    View in: PubMed
    Score: 0.176
  15. HuR Reduces Radiation-Induced DNA Damage by Enhancing Expression of ARID1A. Cancers (Basel). 2019 Dec 13; 11(12).
    View in: PubMed
    Score: 0.175
  16. IL-24 Inhibits Lung Cancer Growth by Suppressing GLI1 and Inducing DNA Damage. Cancers (Basel). 2019 Nov 27; 11(12).
    View in: PubMed
    Score: 0.175
  17. Combinatorial Nanoparticle Delivery of siRNA and Antineoplastics for Lung Cancer Treatment. Methods Mol Biol. 2019; 1974:265-290.
    View in: PubMed
    Score: 0.164
  18. Exosomes as Theranostics for Lung Cancer. Adv Cancer Res. 2018; 139:1-33.
    View in: PubMed
    Score: 0.153
  19. Recent Advances in Nanoparticle-Based Cancer Drug and Gene Delivery. Adv Cancer Res. 2018; 137:115-170.
    View in: PubMed
    Score: 0.153
  20. Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment. Nanomedicine. 2018 02; 14(2):373-384.
    View in: PubMed
    Score: 0.152
  21. Chemodrug delivery using integrin-targeted PLGA-Chitosan nanoparticle for lung cancer therapy. Sci Rep. 2017 11 07; 7(1):14674.
    View in: PubMed
    Score: 0.152
  22. YAP1 inhibition radiosensitizes triple negative breast cancer cells by targeting the DNA damage response and cell survival pathways. Oncotarget. 2017 Nov 17; 8(58):98495-98508.
    View in: PubMed
    Score: 0.151
  23. HuR-targeted small molecule inhibitor exhibits cytotoxicity towards human lung cancer cells. Sci Rep. 2017 08 30; 7(1):9694.
    View in: PubMed
    Score: 0.150
  24. Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth In Vitro and In Vivo By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR. Mol Cancer Ther. 2017 08; 16(8):1470-1486.
    View in: PubMed
    Score: 0.147
  25. Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems. Drug Dev Ind Pharm. 2017 Sep; 43(9):1391-1401.
    View in: PubMed
    Score: 0.147
  26. Polymeric Nanoparticle-Mediated Gene Delivery for Lung Cancer Treatment. Top Curr Chem (Cham). 2017 Apr; 375(2):35.
    View in: PubMed
    Score: 0.145
  27. Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy. Oncol Rep. 2017 Apr; 37(4):2382-2390.
    View in: PubMed
    Score: 0.145
  28. Nanosomes carrying doxorubicin exhibit potent anticancer activity against human lung cancer cells. Sci Rep. 2016 12 12; 6:38541.
    View in: PubMed
    Score: 0.142
  29. Nanoparticles for siRNA-Based Gene Silencing in Tumor Therapy. IEEE Trans Nanobioscience. 2016 12; 15(8):849-863.
    View in: PubMed
    Score: 0.142
  30. IL-24 modulates the high mobility group (HMG) A1/miR222 /AKT signaling in lung cancer cells. Oncotarget. 2016 Oct 25; 7(43):70247-70263.
    View in: PubMed
    Score: 0.141
  31. HuR silencing elicits oxidative stress and DNA damage and sensitizes human triple-negative breast cancer cells to radiotherapy. Oncotarget. 2016 10 04; 7(40):64820-64835.
    View in: PubMed
    Score: 0.141
  32. Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration. J Nanobiotechnology. 2016 Jun 21; 14(1):47.
    View in: PubMed
    Score: 0.138
  33. Tumor-targeted and pH-controlled delivery of doxorubicin using gold nanorods for lung cancer therapy. Int J Nanomedicine. 2015; 10:6773-88.
    View in: PubMed
    Score: 0.132
  34. HuR-targeted nanotherapy in combination with AMD3100 suppresses CXCR4 expression, cell growth, migration and invasion in lung cancer. Cancer Gene Ther. 2015 Dec; 22(12):581-90.
    View in: PubMed
    Score: 0.132
  35. Phosphorylation of interleukin (IL)-24 is required for mediating its anti-cancer activity. Oncotarget. 2015 Jun 30; 6(18):16271-86.
    View in: PubMed
    Score: 0.129
  36. Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/Plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells. Mol Pharm. 2014 Aug 04; 11(8):2720-33.
    View in: PubMed
    Score: 0.120
  37. Cancer stem cells: progress and challenges in lung cancer. Stem Cell Investig. 2014; 1:9.
    View in: PubMed
    Score: 0.118
  38. Nanodrug delivery systems: a promising technology for detection, diagnosis, and treatment of cancer. AAPS PharmSciTech. 2014 Jun; 15(3):709-21.
    View in: PubMed
    Score: 0.117
  39. Molecular targets and signaling pathways regulated by interleukin (IL)-24 in mediating its antitumor activities. J Mol Signal. 2013 Dec 30; 8(1):15.
    View in: PubMed
    Score: 0.116
  40. MDA-7/IL-24-based cancer gene therapy: translation from the laboratory to the clinic. Curr Gene Ther. 2006 Feb; 6(1):73-91.
    View in: PubMed
    Score: 0.067
  41. Adenovirus-mediated mda-7 (IL24) gene therapy suppresses angiogenesis and sensitizes NSCLC xenograft tumors to radiation. Mol Ther. 2004 Jun; 9(6):818-28.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.